-
Posted by
Two Blokes Apr 25 -
Filed in
Stock
-
3 views
First-quarter results from GSK PLC (LSE:GSK, NYSE:GSK) will focus on commentary around the outlook, including interpretation of US policy changes under vaccine sceptic health secretary Robert Kennedy Jnr, including recent vaccine performance in the US and China. Weakness in the first quarter is anticipated in the US from GSK's key vaccine franchises, RSV vaccine Arexvy and shingles vaccine Shingrix.
